甲状腺疾病治疗市场规模、份额和成长分析（按类型、药物、给药途径、分销管道和地区）- 2025-2032 年产业预测

2023 年甲状腺疾病治疗市场规模价值 26 亿美元，预计将从 2024 年的 27 亿美元增长到 2032 年的 37 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.0%。

由于人口老化导致甲状腺功能亢进等疾病的发病率上升、医疗技术的进步以及对早期诊断和治疗认识的提高，全球甲状腺疾病治疗市场正在经历显着增长。创新的个人化和标靶治疗正在涌现，北美和欧洲由于疾病盛行率高和医疗支出高而成为主要市场。由于医疗保健基础设施的改善和人们意识的提高，拉丁美洲和亚太地区的新兴经济体提供了巨大的成长机会。远端医疗也变得越来越普遍，增加了患者获得内分泌服务的机会。儘管存在诊断设施有限和治疗费用高昂等挑战，甲状腺疾病治疗市场的整体前景仍然乐观，表明未来几年将具有弹性并持续扩张。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究

甲状腺疾病治疗市场规模（按类型和复合年增长率）（2025-2032）

• 市场概况
• 甲状腺机能低下症
• 甲状腺功能亢进

甲状腺疾病治疗市场规模（按药物类型和复合年增长率） (2025-2032)

• 市场概况
• 左旋甲状腺素
• 三碘甲状腺胺酸
• 丙硫氧嘧啶
• 咪唑化合物
• 其他的

甲状腺疾病治疗市场规模（按给药途径和复合年增长率） (2025-2032)

• 市场概况
• 口服
• 静脉
• 其他的

甲状腺疾病治疗市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 批发的
• 零售商
• 网路药局
• 其他的

甲状腺疾病治疗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• AbbVie Inc.（USA）
• Amgen Inc.（USA）
• GSK Plc（UK）
• Merck KGaA（Germany）
• Viatris Inc.（USA）
• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Exelixis Inc.（USA）
• Abbott Laboratories（USA）
• Fresenius SE & Co. KGaA（Germany）
• Jerome Stevens Pharmaceuticals Inc.（USA）
• Lannett Co. Inc.（USA）

结论和建议

Thyroid Gland Disorders Treatment Market size was valued at USD 2.6 billion in 2023 and is poised to grow from USD 2.7 billion in 2024 to USD 3.7 billion by 2032, growing at a CAGR of 4.0% during the forecast period (2025-2032).

The global market for thyroid gland disorder treatments has seen remarkable growth due to the rising incidence of conditions like hyperthyroidism, driven by an aging population, advancements in medical technology, and heightened awareness of early diagnosis and treatment. Innovative personalized medicine and targeted therapies have emerged, positioning North America and Europe as key markets due to higher prevalence rates and healthcare expenditures. Emerging economies in Latin America and Asia-Pacific present significant growth opportunities, fueled by improved healthcare infrastructure and increased awareness. Telemedicine is also gaining traction, enhancing patient access to endocrinology services. Despite challenges such as limited diagnostic facilities and high treatment costs, the overall outlook for the thyroid disorder treatment market remains positive, suggesting resilience and continued expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Thyroid Gland Disorders Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Thyroid Gland Disorders Treatment Market Segments Analysis

Global Thyroid Gland Disorders Treatment Market is segmented by Type, Drug, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Hypothyroidism and Hyperthyroidism. Based on Drug, the market is segmented into Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based compounds and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous and Others. Based on Distribution Channel, the market is segmented into Wholesale Distribution, Retail Stores, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Thyroid Gland Disorders Treatment Market

The global prevalence of thyroid disorders, including hyperthyroidism, hypothyroidism, and various forms of thyroid cancer, is on the rise, largely due to increasing mental stress and changing lifestyle factors. Environmental influences have also contributed to the surge in these conditions, leading to a greater need for effective treatments. Consequently, the market for thyroid gland disorder treatments has expanded significantly to accommodate the growing patient population seeking specialized medical care for their conditions. This escalating demand is driving innovation and investment in therapeutic options, underscoring the importance of addressing thyroid health in today's world.

Restraints in the Thyroid Gland Disorders Treatment Market

The pricey nature of prescription medications significantly impacts patients undergoing long-term treatment for thyroid disorders, creating a considerable barrier. Therapeutic options, such as radioactive iodine therapy and surgical interventions, often incur substantial costs, which can be prohibitive for many individuals. This challenge is especially pronounced for those residing in regions with limited healthcare access or inadequate health insurance coverage, making these essential treatments a major financial strain. Consequently, the high expenses associated with thyroid gland disorder therapies can hinder patients from receiving timely and necessary medical attention, ultimately affecting their overall health and well-being.

Market Trends of the Thyroid Gland Disorders Treatment Market

The thyroid gland disorders treatment market is experiencing significant growth propelled by rising incidence rates worldwide. This trend has prompted pharmaceutical companies to intensify their research and development efforts, resulting in advanced treatment options that cater to an expanding patient population. Key market players are focused on innovation, striving to develop more effective and affordable therapies. These innovations not only aim to enhance overall patient outcomes but also prioritize minimizing side effects and improving quality of life. As a result, the market is poised for sustained growth, reflecting a proactive response to the increasing need for effective thyroid disorder management solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Thyroid Gland Disorders Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Hypothyroidism
• Hyperthyroidism

Global Thyroid Gland Disorders Treatment Market Size by Drug & CAGR (2025-2032)

• Market Overview
• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-based compounds
• Others

Global Thyroid Gland Disorders Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous
• Others

Global Thyroid Gland Disorders Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Wholesale Distribution
• Retail Stores
• Online Pharmacy
• Others

Global Thyroid Gland Disorders Treatment Market Size & CAGR (2025-2032)

• North America (Type, Drug, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jerome Stevens Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lannett Co. Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations